Rhythm (RYTM) Q2 Revenue Jumps 67%

Rhythm Pharmaceuticals reported Q2 2025 GAAP revenue of $48.5 million, up 66.7% year-over-year and surpassing analyst estimates by 11.1% due to strong IMCIVREE commercial uptake. However, the company's GAAP net loss widened to ($0.75) per share, missing expectations, driven by sharply increased R&D and SG&A expenses reflecting significant investment in pipeline advancement, including positive Phase 3 setmelanotide data and Phase 2 bivamelagon results, and global commercial expansion. A recent $189.2 million capital raise has bolstered liquidity, extending their operating runway to at least 24 months to support these strategic growth initiatives.

Analysis

Rhythm Pharmaceuticals (RYTM) reported a mixed but strategically coherent Q2 2025, characterized by robust top-line growth offset by significant, planned investments in its future. GAAP revenue surged 66.7% year-over-year to $48.5 million, decisively beating analyst forecasts by 11.1% on the back of strong commercial uptake for its lead product, IMCIVREE. However, this was coupled with a wider-than-expected GAAP net loss of ($0.75) per share, missing the consensus estimate of ($0.67). This loss was driven by a sharp, deliberate increase in operating expenses, with R&D costs rising 40.1% and SG&A expenses growing 26.1% year-over-year. These expenditures are directly tied to value-creating activities, including advancing setmelanotide through a successful Phase 3 trial that showed a 19.8% placebo-adjusted BMI reduction, and progressing the next-generation oral agonist, bivamelagon, which posted positive Phase 2 results. The company proactively addressed potential balance sheet concerns by raising approximately $189.2 million in net proceeds from a stock offering in July, subsequent to the quarter's end, extending its operational runway to a guided minimum of 24 months. This positions the company to fund its pipeline through key regulatory and clinical milestones without immediate financing pressure.

Key Decisions for Investors

• Investors should weigh the confirmed commercial execution, evidenced by the 66.7% revenue growth, against the widening net loss, recognizing that the increased spending is fueling a de-risked late-stage pipeline.
• The primary focus should be on upcoming catalysts, particularly the planned Q3 2025 regulatory submissions for setmelanotide, as approvals would validate the current investment thesis and open a significant new market.
• Monitor cash burn relative to the company's guided 24-month runway, as any delays in clinical progress or commercial launches could heighten the risk of future shareholder dilution.